# US Cortisone Shots Market > US Cortisone Shots Market Research Report By Type (articular or joint injections, epidural steroid injection, trigger point injection, others), By Indication (rheumatoid arthritis, psoriatic arthritis, bursitis, allergic reaction, skin conditions, others) and By End User (hospitals, clinics, sport medicine centers, pharmaceutical companies, others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.42% - **2024:** $ 450 Million - **2025:** $ 483.39 Million - **2035:** $ 989.14 Million - **Key Players:** Pfizer (US), Merck (US), Bristol-Myers Squibb (US), Sanofi (FR), Amgen (US), AbbVie (US), Hikma Pharmaceuticals (GB), Mylan (US), Teva Pharmaceutical Industries (IL) **Report ID:** MRFR/Pharma/18363-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-cortisone-shots-market-19910 --- ## Market Summary ## **US Cortisone Shots Market Overview** As per MRFR analysis, the US Cortisone Shots Market Size was estimated at 575.4 (USD Million) in 2023. The US Cortisone Shots Market Industry is expected to grow from 650(USD Million) in 2024 to 1,300 (USD Million) by 2035. The US Cortisone Shots Market CAGR (growth rate) is expected to be around 6.504% during the forecast period (2025 - 2035). ### **Key US Cortisone Shots Market Trends Highlighted** The US Cortisone Shots Market is witnessing significant trends driven by the increasing prevalence of conditions such as arthritis, bursitis, and other inflammatory disorders. The aging population in the United States is a major market driver, as older adults are more likely to suffer from these conditions and seek treatment options. Additionally, the growing awareness of non-surgical treatment options for pain relief is encouraging patients and healthcare providers to consider cortisone shots as a viable alternative. The accessibility and ease of administration of these injections further contribute to their popularity in outpatient settings, making them a preferred choice for many healthcare practitioners. There are notable opportunities in the US market that can be explored, particularly in terms of advancements in medical technology and improved injection techniques. These advancements can enhance the effectiveness of cortisone shots, leading to higher patient satisfaction and better outcomes. A focus on personalized treatment plans, based on individual patient needs, could also enhance the demand for these injections. Moreover, the rise of telemedicine post-pandemic has opened new avenues for consultations, allowing patients to receive expert advice on cortisone shot therapies more conveniently. In recent times, there has been an increasing trend towards research and clinical studies examining the long-term efficacy and safety of cortisone injections. This research is crucial in providing clinicians with a clearer understanding of the treatment's benefits versus potential risks. Moreover, there is a growing emphasis on integrating cortisone shots into broader pain management strategies, reflecting a more holistic approach to treating chronic conditions. As the healthcare landscape in the US continues to evolve, these trends indicate a robust outlook for the Cortisone Shots Market in the coming years. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Cortisone Shots Market Drivers** ### **Increasing Prevalence of Chronic Diseases** The rising prevalence of chronic diseases, particularly among the aging population in the United States, is significantly driving the growth of the US [Cortisone Shots Market](../../../reports/cortisone-shots-market-4847) Industry. According to the Centers for Disease Control and Prevention, approximately 60% of adults in the US have a chronic disease, while 40% have two or more. Conditions such as arthritis, autoimmune diseases, and orthopedic issues that are treated frequently with cortisone shots have surged, particularly due to the aging Baby Boomer demographic, which is projected to continue to grow as they reach older age brackets. Major health organizations, including the American Arthritis Foundation, estimate that by 2030, more than 67 million US adults will have doctor-diagnosed arthritis. This significant increase in patients requiring cortisone treatments elevates the demand for cortisone shots, hence driving market growth. ### **Technological Advancements in Injection Techniques** Innovations in injection techniques and the development of advanced corticosteroid medications are poised to enhance the efficacy and safety of cortisone shots, contributing favorably to the US Cortisone Shots Market Industry. The advent of ultrasound-guided injections allows for more precise targeting of the affected areas, reducing patient discomfort and improving outcomes. According to the American Society of Regional Anesthesia and Pain Medicine, the use of ultrasound guidance can increase the success rate of these procedures by over 50%.This increased effectiveness, supported by organizations like the American Medical Association, is likely to boost the adoption of cortisone injections in clinical practices across the US, thereby propelling market growth. ### **Rising Awareness and Acceptance of Corticosteroid Treatments** Growing public awareness and acceptance of corticosteroid treatments, notably cortisone shots, are significantly influencing the expansion of the US Cortisone Shots Market Industry. Public health campaigns led by reputable organizations like the National Institutes of Health have highlighted the benefits and effectiveness of corticosteroids in alleviating pain and inflammation associated with various conditions. This advocacy has led to an increase in patients proactively seeking cortisone shots as a treatment option. According to a national health survey, around 30% of adults have indicated a willingness to consider corticosteroid treatments following educational campaigns about their benefits, which, in turn, is anticipated to drive market growth. ## **US Cortisone Shots Market Segment Insights** ### **Cortisone Shots Market Type Insights** The US Cortisone Shots Market presents a significant opportunity for healthcare providers and patients alike, particularly in the Type segment, which encompasses various injection methods utilized for pain relief and inflammation reduction. Among these, articular or joint injections are pivotal, targeting inflamed joints effectively to enhance mobility and quality of life for patients suffering from conditions like arthritis. This particular method has gained traction due to its direct approach in delivering therapeutic agents precisely where they are needed. Epidural steroid injections represent another notable aspect of the Type segment, providing relief for patients grappling with back pain and related neurological symptoms due to spinal nerve compression. This method has seen an increase in acceptance as it offers targeted pain management, improving functionality and reducing reliance on systemic medications. Meanwhile, trigger point injections have carved out their own niche by addressing myofascial pain syndromes, which are prevalent in both active individuals and those in sedentary jobs. This technique often results in rapid relief and promotes recovery without the prolonged use of medication. Each of these injection types has its own unique benefits and applications, making them critical components of the overall US Cortisone Shots Market dynamics.The market also includes other forms of injections that cater to a variety of conditions beyond the commonly used ones, providing a broader spectrum for pain management solutions. As the prevalence of musculoskeletal disorders increases, the importance of the Type segment in the US Cortisone Shots Market is underscored, aligning well with the growing demand for efficient pain management strategies.  Understanding the intricacies of these injection types not only helps healthcare professionals offer personalized treatments but also highlights opportunities for innovation and development within the industry. This dynamic landscape is driven by factors such as ongoing advancements in injection techniques, patient awareness of treatment options, and the increasing burden of chronic pain conditions within the US population, all of which contribute to the robust growth potential of the US Cortisone Shots Market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Cortisone Shots Market Indication Insights** The US Cortisone Shots Market is primarily segmented by Indication, which includes various conditions such as rheumatoid arthritis, psoriatic arthritis, bursitis, allergic reactions, skin conditions, and others. Rheumatoid arthritis remains a critical area due to its chronic nature and the need for effective anti-inflammatory treatment, making cortisone shots a preferred option for many patients. Similarly, psoriatic arthritis is notable for its significant impact on patient mobility and quality of life, driving the demand for cortisone interventions. Bursitis, often resulting from repetitive motions or injuries, highlights the importance of cortisone shots in providing relief for individuals involved in physically demanding occupations. Allergic reactions and skin conditions show the versatility of cortisone shots, as they are used to manage symptoms from a range of diseases, underscoring their relevance in dermatological treatments. The diverse spectrum of indications emphasizes not only the applications of cortisone shots in clinical practice but also presents numerous growth opportunities within the US Cortisone Shots Market, with increasing awareness and research focused on effective treatment options for these conditions. ### **Cortisone Shots Market End User Insights** The US Cortisone Shots Market is significantly influenced by various End User categories, which include hospitals, clinics, sports medicine centers, pharmaceutical companies, and others. Hospitals tend to dominate this market due to their extensive patient bases and ability to provide a wide range of treatments, including advanced procedures. Clinics play a pivotal role as well, as they offer outpatient services that are crucial for administering cortisone shots effectively. Sports medicine centers are also key players, catering to athletes who benefit from these injections for injury recovery and pain management, highlighting the shots' importance in sports-related therapies. Pharmaceutical companies remain integral, producing and supplying essential medications used in cortisone shots. The overall trends in the US healthcare landscape, such as an increase in chronic diseases and an aging population, are expected to drive the demand for cortisone shots. Additionally, opportunities for growth exist in enhancing treatment protocols and advancing the formulation of injectable steroids, thereby enhancing efficacy and patient outcomes. The diversification across the End User spectrum presents a holistic view of the market dynamics, reflecting the broad applicability of cortisone shots in managing various health conditions. ## **US Cortisone Shots Market Key Players and Competitive Insights** The US Cortisone Shots Market is characterized by a dynamic and competitive landscape where innovation, regulatory compliance, and pricing strategies play vital roles. The growing prevalence of chronic inflammatory conditions, alongside an aging population, has led to a rising demand for corticosteroid injections. As healthcare providers and patients seek effective pain management solutions, various pharmaceutical companies are striving to leverage their market positions.  The competitive insights within this market reveal not only the strategic initiatives undertaken by key players but also their ability to adapt to changing healthcare policies and consumer needs. This competition is further intensified by the introduction of generic alternatives, which impacts pricing and access for patients. Furthermore, the regulatory environment surrounding the approval and marketing of cortisone shots necessitates that companies remain vigilant and compliant, ensuring the safety and efficacy of their products. Teva Pharmaceutical Industries stands out in the US Cortisone Shots Market due to its robust product portfolio and strong presence in the prescription medication segment. With a commitment to delivering high-quality and affordable healthcare solutions, Teva leverages its extensive experience in the pharmaceuticals sector to offer a variety of cortisone preparations, catering to different patient needs.  The company’s strategic focus on research and development enables it to enhance its product offerings continually, thereby solidifying its competitive edge. Teva's established relationships with healthcare providers and its adaptive market strategies enable it to maintain significant visibility and accessibility in this niche segment, aiding patients in managing troubling conditions effectively. The company's infrastructure supports large-scale production and distribution, ensuring that medication availability remains consistent. Merck and Co is another prominent player in the US Cortisone Shots Market, known for its commitment to innovation and patient care. With a well-structured portfolio that includes cortisone-based solutions, Merck emphasizes research-driven development that aligns with critical therapeutic needs. Their products are designed to address inflammatory and autoimmune conditions, which are prevalent in the US. Merck benefits from strong market presence thanks to its reputable brand image and trust among healthcare professionals and patients alike.  The company has pursued various mergers and acquisitions strategically aimed at expanding its capabilities and enhancing its service offerings within the cortisone market. This approach not only strengthens their portfolio but also permits them to leverage cutting-edge technology for product development. Merck remains focused on delivering effective treatments while ensuring compliance with industry regulations, thus reinforcing its competitive position in the dynamic landscape of cortisone shots in the US. ### **Key Companies in the US Cortisone Shots Market Include** - Teva Pharmaceutical Industries - Merck and Co - Novartis - **[AstraZeneca](https://www.astrazeneca.com/media-centre/press-releases/2024/az-unveils-latest-research-across-key-respiratory-and-immune-mediated-diseases-at-ats-2024-showcasing-strength-of-its-broad-pipeline-and-portfolio.html)** - Eli Lilly - BristolMyers Squibb - Sandoz - Regeneron Pharmaceuticals - Pfizer - Amgen - AbbVie - Hikma Pharmaceuticals - Sanofi - Johnson and Johnson - Mylan ### **US Cortisone Shots Market Industry Developments** The US Cortisone Shots Market has seen notable developments recently. Companies like Teva Pharmaceutical Industries and Novartis have been refining their cortisone formulations to enhance efficacy and reduce side effects, influenced by the increasing patient demand for more effective pain management solutions. Additionally, AstraZeneca's research has focused on the underlying mechanisms of inflammation, leading to potential advancements in cortisone therapy.  In terms of mergers and acquisitions, Merck and Co announced plans to acquire a smaller biopharmaceutical firm specialized in inflammation which completed in April 2023. This acquisition is expected to bolster Merck's portfolio in the pain management sector. Furthermore, growth in market valuation is observed, with industry estimates projecting a compound annual growth rate of over 5% through 2025, driven by rising orthopedic and inflammatory disorders in the US.Moreover, the increase in regulatory approvals for new cortisone formulations, such as those from Bristol-Myers Squibb and Regeneron Pharmaceuticals over the past 2-3 years, underlines the competitive nature of the market. Overall, the US Cortisone Shots Market remains dynamic, with continuous advancements and strategic collaborations shaping its future landscape. ## **US Cortisone Shots Market Segmentation Insights** ### **Cortisone Shots Market Type Outlook** - articular or joint injections - epidural steroid injection - trigger point injection - others ### **Cortisone Shots Market Indication Outlook** - rheumatoid arthritis - psoriatic arthritis - bursitis - allergic reaction - skin conditions - others ### **Cortisone Shots Market End User Outlook** - hospitals - clinics - sport medicine centers - pharmaceutical companies - others ## Market Drivers ### Rising Healthcare Expenditure the cortisone shots market is positively influenced by the rising healthcare expenditure in the US. As individuals and families allocate more resources towards healthcare, there is a corresponding increase in the utilization of various medical treatments, including cortisone injections. According to the National Health Expenditure Accounts, healthcare spending in the US is projected to reach approximately $6 trillion by 2027. This increase in expenditure is likely to facilitate greater access to cortisone shots, as patients seek effective solutions for managing pain and inflammation. Consequently, the cortisone shots market may experience significant growth as more patients opt for these injections as part of their treatment plans. ### Expansion of Outpatient Services the expansion of outpatient services contributes to the growth of the cortisone shots market. With a shift towards outpatient care, patients are increasingly receiving cortisone injections in outpatient settings rather than inpatient facilities. This trend is driven by the desire for convenience, reduced costs, and shorter recovery times associated with outpatient procedures. As healthcare systems adapt to this model, the cortisone shots market is likely to see an uptick in demand, as more patients are able to access these treatments without the need for hospitalization. The emphasis on outpatient care aligns with broader healthcare trends aimed at improving patient experiences and outcomes, suggesting a favorable environment for the cortisone shots market. ### Increasing Prevalence of Chronic Conditions The cortisone shots market is experiencing growth due to the rising prevalence of chronic conditions such as arthritis, tendinitis, and bursitis. According to the Centers for Disease Control and Prevention (CDC), approximately 54 million adults in the US have been diagnosed with arthritis, which significantly contributes to the demand for cortisone shots. These injections provide relief from inflammation and pain, making them a preferred choice for many patients. As the population ages, the incidence of these chronic conditions is likely to increase, further driving the cortisone shots market. The ability of cortisone shots to offer quick relief without the need for invasive procedures enhances their appeal among both patients and healthcare providers, indicating a robust growth trajectory for the industry in the coming years. ### Growing Awareness of Pain Management Options There is a notable increase in awareness regarding various pain management options, which is positively impacting the cortisone shots market. Patients are becoming more informed about the benefits of cortisone injections as a viable alternative to surgical interventions. Educational campaigns by healthcare professionals and organizations are emphasizing the effectiveness of cortisone shots in managing pain and inflammation. This heightened awareness is likely to lead to an increase in patient inquiries and consultations regarding cortisone injections. Furthermore, the cortisone shots market is projected to expand as more patients seek non-invasive solutions for their pain management needs, potentially leading to a shift in treatment paradigms within the healthcare system. ### Technological Innovations in Injection Methods Technological advancements in injection techniques are playing a crucial role in shaping the cortisone shots market. Innovations such as ultrasound-guided injections and the development of specialized delivery systems have improved the accuracy and efficacy of cortisone shots. These advancements not only enhance patient outcomes but also reduce the risk of complications associated with traditional injection methods. As healthcare providers adopt these new technologies, the cortisone shots market is likely to benefit from increased patient satisfaction and trust in the treatment. The integration of technology into the administration of cortisone shots may also lead to a broader acceptance of these injections among patients, further propelling market growth. ## Future Outlook the [Cortisone Shots Market](https://www.marketresearchfuture.com/reports/cortisone-shots-market-4847) is projected to grow at a CAGR of 7.42% from 2025 to 2035, driven by increasing demand for pain management and advancements in injection techniques. **New opportunities:** - Development of mobile app platforms for patient scheduling and education. - Expansion of telehealth services for remote cortisone shot consultations. - Partnerships with sports organizations for exclusive pain management programs. By 2035, the cortisone shots market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Epidural Steroid Injection (Largest) vs. Trigger Point Injection (Fastest-Growing) In the US cortisone shots market, the distribution of market share among different injection types reveals that articular or joint injections hold a significant portion of the market. However, epidural steroid injections stand out as the largest segment, capturing a substantial share due to their efficacy in treating chronic pain conditions. Trigger point injections, while smaller in share, are experiencing increased adoption due to their effectiveness in managing localized muscular pain. The growth trends within this segment indicate a rising preference for minimally invasive procedures, with both epidural steroid injections and trigger point injections gaining traction. Drivers such as an aging population and a growing incidence of musculoskeletal disorders have led to an uptick in demand. Additionally, advancements in injection techniques and increased awareness of treatment options are contributing factors that are fostering market growth across these segments. Epidural Steroid Injection (Dominant) vs. Trigger Point Injection (Emerging) Epidural steroid injections currently dominate the market due to their effectiveness in treating conditions like sciatica and herniated discs, making them a go-to choice for pain management specialists. They provide considerable relief to patients suffering from chronic back pain, which explains their predominant position in the US cortisone shots market. In contrast, trigger point injections are emerging as a popular option for treating myofascial pain syndrome, with increasing recognition among healthcare providers. These injections focus on deactivating painful trigger points in muscles, leading to reduced pain and improved mobility. With growing clinical evidence supporting their use and patient satisfaction, trigger point injections are experiencing robust growth, catering to a diverse demographic seeking relief from localized pain. ### By Indication: Rheumatoid Arthritis (Largest) vs. Psoriatic Arthritis (Fastest-Growing) In the US cortisone shots market, the indication segment is primarily dominated by rheumatoid arthritis, accounting for a significant portion of the overall market share. This is followed by psoriatic arthritis and bursitis, which also occupy notable positions in the market. Allergic reactions, skin conditions, and other indications contribute to a smaller share, reflecting more niche applications for cortisone shots in various therapeutic areas. Growth trends within this segment are largely driven by the increasing prevalence of autoimmune disorders such as rheumatoid arthritis and psoriatic arthritis. Additionally, the rising awareness and acceptance of cortisone injections for managing inflammatory conditions contribute to the growth of these segments. Factors including advancements in injection techniques and overall patient satisfaction further boost demand, particularly in the psoriatic arthritis sector, which is seeing rapid adoption and growth. Rheumatoid Arthritis: Dominant vs. Psoriatic Arthritis: Emerging Rheumatoid arthritis remains the dominant indication in the US cortisone shots market, characterized by its complex and chronic nature, which necessitates ongoing management and treatment strategies. Cortisone shots are widely utilized to alleviate pain and inflammation, enhancing the quality of life for individuals affected by this condition. On the other hand, psoriatic arthritis is emerging rapidly as an important segment, fueled by increasing diagnosis rates and greater recognition of its impact on mobility and well-being. While rheumatoid arthritis typically receives ongoing treatment due to its severity, psoriatic arthritis is capturing attention as healthcare providers aim to offer targeted therapies that meet the needs of this growing patient demographic. ### By End User: Hospitals (Largest) vs. Sports Medicine Centers (Fastest-Growing) In the US cortisone shots market, hospitals dominate the end user segment, holding a significant share due to their widespread facilities and comprehensive care offerings. Following hospitals, clinics and sports medicine centers have been gaining traction, with the former being essential for routine treatments and the latter specializing in injury recovery. Pharmaceutical companies and other entities represent smaller but important segments, contributing to the overall dynamics of this market. Growth trends within the end user segment indicate a robust increase in the demand for cortisone shots, particularly from sports medicine centers, which are experiencing rapid expansion as sports-related injuries rise. The aging population and the increasing prevalence of chronic conditions also bolster the demand, particularly in hospitals and clinics. Furthermore, advancements in medical procedures and increased awareness among patients about cortisone shots are driving growth across all end user categories. Hospitals (Dominant) vs. Sports Medicine Centers (Emerging) Hospitals are the dominant players in the US cortisone shots market, primarily due to their capability to provide comprehensive healthcare services and the necessary infrastructure for administering these treatments. They cater to a vast patient base and leverage multidisciplinary teams for effective pain management. On the other hand, sports medicine centers are emerging as a vital segment, catering to athletes and active individuals seeking specialized care for injuries. These centers focus on rehabilitation and preventative care, utilizing cortisone shots as a critical component of their treatment protocols. The increasing popularity of sports and physical activities contributes to their growth, making them a key player in the evolving landscape of cortisone treatment. ## Competitive Benchmarking The cortisone shots market exhibits a dynamic competitive landscape characterized by a blend of established pharmaceutical giants and emerging players. Key growth drivers include an increasing prevalence of inflammatory conditions, advancements in drug delivery systems, and a growing emphasis on patient-centric care. Major companies such as Pfizer (US), Merck (US), and AbbVie (US) are strategically positioned to leverage their extensive research and development capabilities, focusing on innovation and expanding their product portfolios. These companies are actively pursuing partnerships and collaborations to enhance their market presence, thereby shaping a competitive environment that is both robust and evolving.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. The market structure appears moderately fragmented, with a mix of large multinational corporations and smaller specialized firms. This fragmentation allows for diverse competitive strategies, as key players like Bristol-Myers Squibb (US) and Amgen (US) adopt tailored approaches to meet regional demands while optimizing their operational frameworks. In October Pfizer (US) announced a strategic partnership with a leading telehealth provider to enhance patient access to cortisone shot therapies. This collaboration aims to streamline the patient experience, allowing for remote consultations and follow-up care, which is likely to improve adherence to treatment protocols. Such initiatives reflect a broader trend towards integrating digital health solutions into traditional pharmaceutical offerings, potentially setting a new standard for patient engagement in the cortisone shots market. In September AbbVie (US) launched a new formulation of its cortisone injection, designed to provide longer-lasting relief for patients suffering from chronic pain. This innovation not only addresses a significant unmet need in the market but also positions AbbVie as a leader in therapeutic advancements. The introduction of this product is expected to enhance patient outcomes and solidify AbbVie’s competitive edge in a crowded marketplace.Moreover, in August 2025, Merck (US) expanded its manufacturing capabilities by investing in a new facility dedicated to the production of cortisone shots. This move is indicative of Merck's commitment to meeting increasing demand while ensuring high-quality standards. The expansion is anticipated to bolster supply chain reliability and reduce lead times, which are critical factors in maintaining competitive advantage in the pharmaceutical sector. As of November current competitive trends are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in drug development and patient management. Strategic alliances are becoming more prevalent, as companies recognize the value of collaborative innovation in enhancing their market positions. Looking ahead, competitive differentiation is likely to evolve from traditional price-based strategies to a focus on innovation, technological advancements, and supply chain resilience, reflecting a shift towards a more sophisticated and patient-centric approach in the cortisone shots market. ## Recent News & Developments The US Cortisone Shots Market has seen notable developments recently. Companies like Teva Pharmaceutical Industries and Novartis have been refining their cortisone formulations to enhance efficacy and reduce side effects, influenced by the increasing patient demand for more effective pain management solutions. Additionally, AstraZeneca's research has focused on the underlying mechanisms of inflammation, leading to potential advancements in cortisone therapy.  In terms of mergers and acquisitions, Merck and Co announced plans to acquire a smaller biopharmaceutical firm specialized in inflammation which completed in April 2023. This acquisition is expected to bolster Merck's portfolio in the pain management sector. Furthermore, growth in market valuation is observed, with industry estimates projecting a compound annual growth rate of over 5% through 2025, driven by rising orthopedic and inflammatory disorders in the US.Moreover, the increase in regulatory approvals for new cortisone formulations, such as those from Bristol-Myers Squibb and Regeneron Pharmaceuticals over the past 2-3 years, underlines the competitive nature of the market. Overall, the US Cortisone Shots Market remains dynamic, with continuous advancements and strategic collaborations shaping its future landscape. ## Report Scope | MARKET SIZE 2024 | 450.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 483.39(USD Million) | | MARKET SIZE 2035 | 989.14(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.42% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Pfizer (US), Merck (US), Bristol-Myers Squibb (US), Sanofi (FR), Amgen (US), AbbVie (US), Hikma Pharmaceuticals (GB), Mylan (US), Teva Pharmaceutical Industries (IL) | | Segments Covered | Type, Indication, End User | | Key Market Opportunities | Growing demand for minimally invasive treatments drives innovation in the cortisone shots market. | | Key Market Dynamics | Rising demand for cortisone shots driven by increasing prevalence of inflammatory conditions and evolving treatment protocols. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US cortisone shots market in 2024?** A: The market valuation of the US cortisone shots market was $450.0 Million in 2024. **Q: What is the projected market valuation for the US cortisone shots market by 2035?** A: The projected market valuation for the US cortisone shots market is $989.14 Million by 2035. **Q: What is the expected CAGR for the US cortisone shots market during the forecast period 2025 - 2035?** A: The expected CAGR for the US cortisone shots market during the forecast period 2025 - 2035 is 7.42%. **Q: Which companies are considered key players in the US cortisone shots market?** A: Key players in the US cortisone shots market include Pfizer, Merck, Bristol-Myers Squibb, Sanofi, Amgen, AbbVie, Hikma Pharmaceuticals, Mylan, and Teva Pharmaceutical Industries. **Q: What are the main types of cortisone shots and their market values?** A: The main types of cortisone shots include articular or joint injections valued at $180.0 - $400.0 Million, epidural steroid injections at $150.0 - $300.0 Million, and trigger point injections at $70.0 - $200.0 Million. **Q: What indications are driving the US cortisone shots market?** A: Indications driving the US cortisone shots market include rheumatoid arthritis valued at $90.0 - $200.0 Million and psoriatic arthritis at $60.0 - $130.0 Million. **Q: What are the primary end users of cortisone shots in the US market?** A: Primary end users of cortisone shots in the US market include hospitals valued at $180.0 - $400.0 Million and clinics at $120.0 - $250.0 Million. **Q: How does the market for cortisone shots in hospitals compare to other end users?** A: The market for cortisone shots in hospitals is notably larger, valued at $180.0 - $400.0 Million, compared to clinics at $120.0 - $250.0 Million. **Q: What is the market value range for 'other' types of cortisone shots?** A: The market value range for 'other' types of cortisone shots is $50.0 - $89.14 Million. **Q: What trends are expected to influence the US cortisone shots market in the coming years?** A: Trends influencing the US cortisone shots market may include advancements in injection techniques and increasing prevalence of conditions requiring cortisone treatment. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-cortisone-shots-market-19910*